Recro Pharma Inc. (REPH) 3.13 $REPH
13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
at The Street - Fri Feb 06, 11:55AM CST
Here are the 13 worst performing IPO stocks in 2014.
ROKA: 4.04 (+0.01), SHAK: 40.69 (+0.04), BRDR: 6.15 (+0.04), ECR: 7.29 (+0.12), BIOC: 1.41 (+0.22), ATEN: 4.14 (-0.09), CRCM: 7.98 (-0.07), AMDA: 0.65 (+0.01), MOLG: 2.46 (+0.03), SGNL: 3.91 (+2.15), GBSN: 1.77 (-0.08), FMSA: 6.23 (+0.29), HELI: 2.11 (+0.03), REPH: 3.13 (-0.12)
Recro Pharma Enters Into Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Tue Feb 03, 7:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire Capital"
. Under the new agreement, Recro has the right to sell up to $10 million in shares of common stock to Aspire Capital, subject to certain terms and conditions over a two-year period. The agreement represents an additional tool to provide the Company with additional capital and flexibility.
REPH: 3.13 (-0.12)
Recro Pharma to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:22PM CST
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 11:00 am EST. The conference is being held at the Waldorf Astoria Hotel in New York City.
REPH: 3.13 (-0.12)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
Worst Performing IPOs of 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:10AM CST
The average offering return was at 16% in 2014, significantly lower than 41% in 2013
E: 36.31 (+0.69), SC: 22.11 (+0.38), ALLY: 22.05 (+0.21), FB: 75.74 (-0.49), BIOC: 1.41 (+0.22), NADL: 2.10 (-0.02), RBS: 11.97 (+0.01), ATEN: 4.14 (-0.09), V: 269.63 (-1.28), CFG: 25.45 (+0.12), SYF: 32.80 (-0.81), PGRE: 18.54 (-0.11), NDAQ: 49.48 (-0.27), AM: 24.47 (+0.64), REPH: 3.13 (-0.12), BABA: 89.05 (+1.95)
InsiderInsights.com Daily Round Up 12/4/14: GPRO, XOMA, PSEC, KMT
InsiderInsights - at Seeking Alpha - Fri Dec 05, 5:22PM CST
GPRO: 45.27 (-0.02), CLR: 47.36 (+0.74), PATK: 46.96 (+0.45), JONE: 10.18 (+0.18), RL: 135.20 (-0.60), PRSS: 2.95 (-0.08), KMT: 35.44 (+0.86), TSRA: 39.27 (-0.05), WDAY: 91.84 (+0.67), DYN: 28.39 (+0.01), WRLD: 78.79 (-0.21), OC: 38.72 (+0.19), DATA: 99.90 (+1.40), SFXE: 3.49 (+0.01), PSEC: 8.67 (+0.07), REPH: 3.13 (-0.12), XOMA: 3.41 (-0.01)
Multiple Insiders of Recro Pharma, Inc. (REPH)-NasdaqCM bought Shares of REPH
M2 - Fri Dec 05, 7:56AM CST
Reported by InsiderCow.com at 2014-12-04 10:32:18 ET
REPH: 3.13 (-0.12)
Biotech Weekly: The Value In Beaten-Down Biotech IPOs
Daniel Ward - at Seeking Alpha - Mon Nov 24, 8:26AM CST
ROKA: 4.04 (+0.01), NERV: 4.68 (+0.09), IBB: 323.46 (+3.04), REPH: 3.13 (-0.12)
Recro Pharma misses by $0.10
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:12AM CST
REPH: 3.13 (-0.12)
Recro Pharma Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 6:07AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today reported financial results for the third quarter ended September 30, 2014.
REPH: 3.13 (-0.12)
Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
GlobeNewswire - Wed Oct 29, 3:13PM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced dosing of the first patient in a Phase II clinical trial of Dex-IN in patients who initiate dosing of study medication on Post Op Day 1, following bunionectomy surgery.
REPH: 3.13 (-0.12)
3 Stocks Under $10 Moving Higher
at The Street - Wed Sep 10, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
SKBI: 4.22 (+0.03), REPH: 3.13 (-0.12)
Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced that Gerri Henwood, Recro's President and Chief Executive Officer, will be presenting at the 2014 Aegis Healthcare & Technology Conference on Friday, September 12 at 11:25am PST at The Encore at Wynn Las Vegas.
REPH: 3.13 (-0.12)
Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
GlobeNewswire - Thu Sep 04, 3:51PM CDT
Analgesia in a subset of patients (50%), suggests therapeutic potential for Dex-IN in Post Op Day 1
REPH: 3.13 (-0.12)
Recro Pharma Reports Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 12, 6:08AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today reported financial results for the second quarter ended June 30, 2014.
REPH: 3.13 (-0.12)
Recro Pharma Added to Russell Microcap(R) Index
GlobeNewswire - Mon Jun 30, 6:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced that it was added to the Russell Microcap Index following market close on June 27, 2014.
REPH: 3.13 (-0.12)
Recro Pharma Announces Dosing of First Patient in Phase IIb Clinical Trial of Dex-IN for Treatment of Acute Pain Following Surgery
GlobeNewswire - Tue Jun 17, 6:30AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced dosing of the first patient in a Phase IIb clinical trial of Dex-IN in patients undergoing bunionectomy surgery.
REPH: 3.13 (-0.12)
Recro Pharma (REPH) in Focus: Stock Gains 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:25AM CDT
Recro Pharma (REPH) was a big mover last session, with shares rising over 6% on the day.
OHRP: 7.38 (-0.30), ARIA: 7.35 (+0.45), REPH: 3.13 (-0.12)
13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
at The Street - Fri Feb 06, 11:55AM CST
Here are the 13 worst performing IPO stocks in 2014.
ROKA: 4.04 (+0.01), SHAK: 40.69 (+0.04), BRDR: 6.15 (+0.04), ECR: 7.29 (+0.12), BIOC: 1.41 (+0.22), ATEN: 4.14 (-0.09), CRCM: 7.98 (-0.07), AMDA: 0.65 (+0.01), MOLG: 2.46 (+0.03), SGNL: 3.91 (+2.15), GBSN: 1.77 (-0.08), FMSA: 6.23 (+0.29), HELI: 2.11 (+0.03), REPH: 3.13 (-0.12)
Recro Pharma Enters Into Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Tue Feb 03, 7:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire Capital"
. Under the new agreement, Recro has the right to sell up to $10 million in shares of common stock to Aspire Capital, subject to certain terms and conditions over a two-year period. The agreement represents an additional tool to provide the Company with additional capital and flexibility. REPH: 3.13 (-0.12)
Recro Pharma to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:22PM CST
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 11:00 am EST. The conference is being held at the Waldorf Astoria Hotel in New York City.
REPH: 3.13 (-0.12)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
Worst Performing IPOs of 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:10AM CST
The average offering return was at 16% in 2014, significantly lower than 41% in 2013
E: 36.31 (+0.69), SC: 22.11 (+0.38), ALLY: 22.05 (+0.21), FB: 75.74 (-0.49), BIOC: 1.41 (+0.22), NADL: 2.10 (-0.02), RBS: 11.97 (+0.01), ATEN: 4.14 (-0.09), V: 269.63 (-1.28), CFG: 25.45 (+0.12), SYF: 32.80 (-0.81), PGRE: 18.54 (-0.11), NDAQ: 49.48 (-0.27), AM: 24.47 (+0.64), REPH: 3.13 (-0.12), BABA: 89.05 (+1.95)
InsiderInsights.com Daily Round Up 12/4/14: GPRO, XOMA, PSEC, KMT
InsiderInsights - at Seeking Alpha - Fri Dec 05, 5:22PM CST
GPRO: 45.27 (-0.02), CLR: 47.36 (+0.74), PATK: 46.96 (+0.45), JONE: 10.18 (+0.18), RL: 135.20 (-0.60), PRSS: 2.95 (-0.08), KMT: 35.44 (+0.86), TSRA: 39.27 (-0.05), WDAY: 91.84 (+0.67), DYN: 28.39 (+0.01), WRLD: 78.79 (-0.21), OC: 38.72 (+0.19), DATA: 99.90 (+1.40), SFXE: 3.49 (+0.01), PSEC: 8.67 (+0.07), REPH: 3.13 (-0.12), XOMA: 3.41 (-0.01)
Multiple Insiders of Recro Pharma, Inc. (REPH)-NasdaqCM bought Shares of REPH
M2 - Fri Dec 05, 7:56AM CST
Reported by InsiderCow.com at 2014-12-04 10:32:18 ET
REPH: 3.13 (-0.12)
Biotech Weekly: The Value In Beaten-Down Biotech IPOs
Daniel Ward - at Seeking Alpha - Mon Nov 24, 8:26AM CST
ROKA: 4.04 (+0.01), NERV: 4.68 (+0.09), IBB: 323.46 (+3.04), REPH: 3.13 (-0.12)
Recro Pharma misses by $0.10
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:12AM CST
REPH: 3.13 (-0.12)
Recro Pharma Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 6:07AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today reported financial results for the third quarter ended September 30, 2014.
REPH: 3.13 (-0.12)
Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
GlobeNewswire - Wed Oct 29, 3:13PM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced dosing of the first patient in a Phase II clinical trial of Dex-IN in patients who initiate dosing of study medication on Post Op Day 1, following bunionectomy surgery.
REPH: 3.13 (-0.12)
3 Stocks Under $10 Moving Higher
at The Street - Wed Sep 10, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
SKBI: 4.22 (+0.03), REPH: 3.13 (-0.12)
Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced that Gerri Henwood, Recro's President and Chief Executive Officer, will be presenting at the 2014 Aegis Healthcare & Technology Conference on Friday, September 12 at 11:25am PST at The Encore at Wynn Las Vegas.
REPH: 3.13 (-0.12)
Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
GlobeNewswire - Thu Sep 04, 3:51PM CDT
Analgesia in a subset of patients (50%), suggests therapeutic potential for Dex-IN in Post Op Day 1
REPH: 3.13 (-0.12)
Recro Pharma Reports Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 12, 6:08AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today reported financial results for the second quarter ended June 30, 2014.
REPH: 3.13 (-0.12)
Recro Pharma Added to Russell Microcap(R) Index
GlobeNewswire - Mon Jun 30, 6:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced that it was added to the Russell Microcap Index following market close on June 27, 2014.
REPH: 3.13 (-0.12)
Recro Pharma Announces Dosing of First Patient in Phase IIb Clinical Trial of Dex-IN for Treatment of Acute Pain Following Surgery
GlobeNewswire - Tue Jun 17, 6:30AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced dosing of the first patient in a Phase IIb clinical trial of Dex-IN in patients undergoing bunionectomy surgery.
REPH: 3.13 (-0.12)
Recro Pharma (REPH) in Focus: Stock Gains 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:25AM CDT
Recro Pharma (REPH) was a big mover last session, with shares rising over 6% on the day.
OHRP: 7.38 (-0.30), ARIA: 7.35 (+0.45), REPH: 3.13 (-0.12)
